Gland Pharma share news and announcements
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,826.80down ₹23.60 (0.83%)BSE ₹2,825.35
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,850.40.
52-week range of traded prices to 23 Oct 2026
₹1,573.60Low, 16 Mar 2026₹3,171.00High, 7 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹46,645 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 41.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 4.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,23,05755.6% delivered
Gland Pharma board meetings
44 filed, newest first.
Oct 2026
1 Oct · Board meeting
Sep 2026
13 Sep · Board meeting
Jul 2026
Jun 2026
15 Jun · Board meeting
Apr 2026
9 Apr · Board meeting
Jan 2026
Oct 2025
Jul 2025
May 2025
Feb 2025
26 Feb · Board meeting
3 Feb · Board meeting
Jan 2025
Nov 2024
4 Nov · Board meeting
Oct 2024
Aug 2024
6 Aug · Board meeting
Jul 2024
Jun 2024
7 Jun · Board meeting
May 2024
Apr 2024
29 Apr · Board meeting
Feb 2024
14 Feb · Board meeting
Jan 2024
Nov 2023
6 Nov · Board meeting
Oct 2023
Aug 2023
7 Aug · Board meeting
Jul 2023
May 2023
18 May · Board meeting
Apr 2023
Jan 2023
Oct 2022
Jul 2022
May 2022
Apr 2022
Jan 2022
Dec 2021
Oct 2021
22 Oct · Board meeting
Sep 2021
Jul 2021
21 Jul · Board meeting
Jun 2021
May 2021
17 May · Board meeting
Apr 2021
Jan 2021
22 Jan · Board meeting
Dec 2020